VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 82,600 shares, an increase of 65.2% from the October 15th total of 50,000 shares. Based on an average trading volume of 70,400 shares, the short-interest ratio is currently 1.2 days. Currently, 0.7% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research report on Friday, November 8th.

VYNE Therapeutics Stock Performance

Shares of VYNE stock opened at $2.84 on Friday. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $4.48. The company has a market capitalization of $41.89 million, a price-to-earnings ratio of -3.30 and a beta of 1.32. The company has a 50-day simple moving average of $2.26 and a 200 day simple moving average of $2.19.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.11 million. Sell-side analysts forecast that VYNE Therapeutics will post -0.86 EPS for the current year.

Institutional Trading of VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.